Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.

Abstract

INTRODUCTION:

Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19.

METHODS:

We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients.

RESULTS:

A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables.

CONCLUSION:

We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.

• Authors: Preethi Ramachandran, Abhilash Perisetti, Mahesh Gajendran, Farla Jean-Louis, Pardeep Bansal, Alok Kumar Dwivedi, Hemant Goyal
• Journal: European journal of gastroenterology & hepatology (Eur J Gastroenterol Hepatol) Vol. 34 Issue 2 Pg. 137-141 (02 01 2022) ISSN: 1473-5687 [Electronic] England
• PMID: 33252418 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Proton Pump Inhibitors

Topics

• COVID-19
• Hospitalization
• Humans
• Proton Pump Inhibitors (adverse effects)
• SARS-CoV-2